Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol
- PMID: 18806925
- DOI: 10.1007/s00702-008-0122-8
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol
Abstract
There is increasing evidence supporting the involvement of the muscarinic-cholinergic system in schizophrenia. We examined the M1 muscarinic receptor density and mRNA expression in brains of a rat amphetamine model of schizophrenia. We also assessed the effect of the model and chronic treatment with haloperidol and clozapine on brain M1 receptor density and gene expression. A significant decrease of about 20% in the density of M1 receptor was detected in the cortex and in the striatum of amphetamine model rats. A significant increase of 33% in the density of the M1 receptor was found in the cortex and striatum of rats treated chronically with clozapine (0.5 mg/kg), but not with haloperidol (25 mg/kg). Chronic clozapine, but not haloperidol, normalized the decrease in M1 receptors observed in amphetamine model rats, in both cortex and striatum. Regulation of the M1 receptor may occur in a post-transcriptional phase. Our findings suggest involvement of both dopaminergic and cholinergic-muscarinic systems in the pathophysiology and pharmacotherapy of schizophrenia.
Similar articles
-
Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain: impact of antipsychotic drug treatment.Neuropharmacology. 2012 Mar;62(3):1554-63. doi: 10.1016/j.neuropharm.2011.05.016. Epub 2011 May 27. Neuropharmacology. 2012. PMID: 21640736
-
Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression.Schizophr Res. 2004 Feb 1;66(2-3):151-7. doi: 10.1016/S0920-9964(03)00088-4. Schizophr Res. 2004. PMID: 15061247
-
Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain.J Neurosci Res. 2008 Feb 1;86(2):457-64. doi: 10.1002/jnr.21491. J Neurosci Res. 2008. PMID: 17787019
-
Novel pharmacological approaches to the treatment of schizophrenia.Dan Med Bull. 2000 Jun;47(3):151-67. Dan Med Bull. 2000. PMID: 10913983 Review.
-
Cognitive deficit in schizophrenia and its neurochemical basis.Br J Psychiatry Suppl. 1999;(37):16-8. Br J Psychiatry Suppl. 1999. PMID: 10211135 Review.
Cited by
-
Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.Int J Mol Sci. 2023 Mar 21;24(6):5945. doi: 10.3390/ijms24065945. Int J Mol Sci. 2023. PMID: 36983018 Free PMC article.
-
Distinct Effects of Olanzapine Depot Treatment on Behavior and Muscarinic M1 Receptor Expression in the Triple-Hit Wisket Rat Model of Schizophrenia.Genes Brain Behav. 2025 Feb;24(1):e70015. doi: 10.1111/gbb.70015. Genes Brain Behav. 2025. PMID: 39844699 Free PMC article.
-
Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function.Elife. 2022 May 3;11:e74835. doi: 10.7554/eLife.74835. Elife. 2022. PMID: 35502897 Free PMC article. Clinical Trial.
-
Embryonic amygdalar transplants in adult rats with motor cortex lesions: a molecular and electrophysiological analysis.Front Neurol. 2011 Sep 15;2:59. doi: 10.3389/fneur.2011.00059. eCollection 2011. Front Neurol. 2011. PMID: 21954393 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical